This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
ELISA/assay
product name :
ELISA Assay Kit for Anti-HER-2 h-mAb in Monkey Serum
catalog :
EHC-V1
quantity :
480 tests
price :
1133 USD
product information
company name :
ACROBiosystems
product type :
Kits
catalog :
EHC-V1
product name :
ELISA Assay Kit for Anti-HER-2 h-mAb in Monkey Serum
quantity :
480 tests
price :
1133 USD
quantity & price :
$1133/480tests
target :
Her2
host species :
Monkey
Research :
For Research Use Only
Formulation :
Please contact us for detailed information.
Reconstitution :
See Certificate of Analysis for details of reconstitution instruction and specific concentration.
Storage :
Upon receipt, please store all items at -20℃.
After reconstitution, the stock solution should be kept at -80℃. It is recommended not to freeze thaw more than 3 times. This product is stable after storage at:
Room temperature (RT) for 1 month in lyophilized state;
-20℃ for 1 year in lyophilized state;
-80℃ for 4 months under sterile conditions after reconstitution.
Background :
How a therapeutic antibody is metabolized in the body is pertinently relevant to its efficacy. Therefore, pharmacokinetics study is an important part of the drug development. HER-2 is probably the most targeted molecule in today’s pharmaceutical industry, thanking to the clinical success of Herceptin®. Many investigational anti-HER-2 mAbs are being developed. There is a growing need for a standard assay that can be used to facilitate the study of their pharmacokinetics.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments